Misplaced Pages

Sepsivac

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Pharmaceutical compound
Sepsivac
Clinical data
Other namesMycobacterium w (heat killed)
Identifiers
CAS Number

Sepsivac is a drug developed by Cadila Pharmaceuticals to treat gram-negative sepsis.  The active ingredient is heat-killed Mycobacterium w, a non-pathogenic strain of Mycobacterium. As an immunomodulatory, it modulates the immune system of the body and hence significantly reduces mortality rate in patients with gram negative sepsis. Sepsivac is a drug developed by CSIR and Cadila Pharmaceuticals under New Millennium Indian Technology Leadership Initiative (NMITLI) programme. In many cases, Sepsivac has proven to provide effective care and relief to COVID patients.

Sepsivac is approved by the Drug Controller General of India (DCGI) for treatment of sepsis or septic shock.

Mechanism

In patients with sepsis, in response to an infection, a lot of pro-inflammatory and anti-inflammatory cytokines are generated in the body. However, some of the cytokines also cause inflammation in the organs of the body, which might be harmful. Immunomodulator drugs such as Sepsivac regulate this host immune response. Sepsivac is found to be safe in patients with no systematic side-effects. It can be used in combination with other treatments to manage a patient in critical care setting.

Sepsivac and COVID

Scientists at CSIR found similarities between the clinical characteristics of patients with gram-negative sepsis and COVID-19. In association with Cadila Pharmaceuticals, the researchers are now working on initiating a randomised, blinded, controlled clinical trial to evaluate Sepsivac's efficacy to reduce mortality in critically ill COVID-19 patients. The repurposed drug will boost the immunity of the body and limit the spread of COVID-19 and increase the recovery rate. The clinical trials will be conducted at national hospitals including PGIMER Chandigarh, AIIMS New Delhi, and AIIMS, Bhopal.

References

  1. ^ Singh J (22 April 2020). "Indian Researchers Plan Clinical Trials of Sepsis Drug Against New Coronavirus". The Wire Science. Retrieved 28 April 2020.
  2. Chakrabarti, Ganguly (29 April 2021). "Is there a way to tame the Covid virus?". @businessline. Retrieved 30 April 2021.
  3. "Sepsivac – A First-In-The-World Innovation for Sepsis Management". Cadila Pharma.
  4. Koshy J (2020-04-21). "Coronavirus | Drug for sepsis to be tested for COVID-19". The Hindu. ISSN 0971-751X. Retrieved 28 April 2020.
  5. Paliath S (22 April 2020). "Gram-negative sepsis drug to be trialled for treating critically-ill COVID-19 patients". www.indiaspend.com. Retrieved 28 April 2020.
  6. "Sepsivac to be tested for COVID-19 treatment". The New Indian Express. 24 April 2020. Retrieved 28 April 2020.
  7. Ray K (23 April 2020). "50-yr-old bacteria drug makes a comeback in fight against coronavirus". Deccan Herald. Retrieved 28 April 2020.


Stub icon

This article about the COVID-19 pandemic is a stub. You can help Misplaced Pages by expanding it.

Categories: